Xtant Medical (NYSEAMERICAN:XTNT) Stock Price Passes Above Two Hundred Day Moving Average – Here’s Why

Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.54. Xtant Medical shares last traded at $0.54, with a volume of 91,934 shares.

Xtant Medical Trading Up 12.5 %

The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 0.88. The stock has a 50-day moving average price of $0.54. The stock has a market capitalization of $75.07 million, a P/E ratio of -4.15 and a beta of 0.35.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xtant Medical stock. Renaissance Technologies LLC increased its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 15.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 798,033 shares of the medical device company’s stock after acquiring an additional 103,825 shares during the period. Renaissance Technologies LLC owned 0.57% of Xtant Medical worth $354,000 as of its most recent filing with the SEC. 69.33% of the stock is currently owned by institutional investors and hedge funds.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.